This announcement is a separate document:
康諾亞-B：自願性公告 司普奇拜單抗治療成人中重度特應性皮炎的藥品上市許可申請獲國家藥品監督管理局受理
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF STAPOKIBART FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN ADULTS ACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.